Ampio Pharma Stock Price, News & Analysis

Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) has announced that it has regained compliance with the NYSE American's continued listing standards, resolving a previously reported deficiency related to its low selling price. Effective December 27, 2022, the company will no longer be indicated as noncompliant and has been removed from the NYSE American noncompliant issuers list. Ampio is currently focused on the development of AR-300, a synthetic drug in preclinical studies, while exploring strategic alternatives to enhance its pipeline.

Ampio Pharmaceuticals, Inc. announced a fifteen-to-one reverse stock split effective November 9, 2022, at 4:01 p.m. ET. This consolidation will reduce the number of shares from 226,286,867 to approximately 15,095,790 shares, aiming to boost the stock price and potentially lift a trading suspension from the NYSE American. The company maintains 310,000,000 authorized shares, unchanged post-split. After the split, trading will commence on the OTC Pink Open Market from November 10, 2022.

Ampio Pharmaceuticals, Inc. announced on October 14, 2022, the approval of a reverse stock split by its stockholders, aimed at resuming trading on the NYSE American after a suspension since October 3, 2022. The company plans to implement this split following regulatory approvals. They have submitted an appeal to the NYSE regarding the trading suspension and are exploring options to move to the OTCQB Venture Market if necessary. Ampio is also advancing preclinical studies on its product AR-300 and focusing on operational efficiencies to conserve cash.

Ampio Pharmaceuticals (AMPE) has urged stockholders to vote 'FOR' a proposed reverse stock split ahead of an upcoming Special Stockholder meeting on October 13, 2022. This action is critical as the NYSE American has determined that the company is no longer suitable for listing due to low trading prices, leading to a suspension and potential delisting. Starting October 4, 2022, AMPE will trade on OTC Markets. The company believes that a successful reverse stock split could help regain its NYSE listing and facilitate strategic opportunities, which would be beneficial for stockholders.

Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) has received notification from NYSE American to commence delisting proceedings due to its common stock's low trading price. Trading has been suspended, and the company has the right to appeal within seven days. In response, Ampio's Board has proposed a reverse stock split, with a special meeting scheduled for October 13, 2022, to seek shareholder approval. Meanwhile, the stock will trade on OTC Pink under the symbol "AMPE," but future trading is uncertain.

Ampio Pharmaceuticals (NYSE American: AMPE) provided a letter to stockholders on August 3, 2022, detailing the outcomes of an independent investigation into its AP-013 clinical trial and unauthorized use of Ampion. The findings indicated that former executives failed to report negative efficacy results. The company has terminated two executives and restructured its Board of Directors. Despite conducting seven trials with over 1,500 patients, Ampion did not show significant benefits over saline, leading to a halt in further pivotal trials. A reverse stock split proposal is crucial for maintaining NYSE American compliance.

Ampio Pharmaceuticals (AMPE) released a letter from CEO Mike Martino to stockholders on June 2, 2022, addressing strategic alternatives for Ampion™ and the ongoing internal investigation. The Phase 3 clinical trial (AP-013) for Ampion showed no statistical benefit when compared to saline on key endpoints. However, a prior trial (AP-003-A) demonstrated significant pain reduction. The COVID-19 trials failed to yield meaningful results, prompting a pause in that program. Financially, the company reported $28.8 million in cash as of March 31, 2022, projecting a burn rate of $1.2-1.3 million monthly until September 2022.

Ampio Pharmaceuticals, Inc. (AMPE) reported a net loss of $5.6 million for Q1 2022, compared to $3.7 million in Q1 2021. Research and development expenses increased to $3.7 million from $2.3 million in the previous year, primarily due to clinical trials and salaries. General and administrative expenses rose to $3.3 million from $1.5 million, driven by higher salaries and stock-based compensation. Cash and cash equivalents decreased to $28.8 million from $33.9 million, with sufficient liquidity expected to fund operations into H2 2023.

Ampio Pharmaceuticals (NYSE American: AMPE) announced on May 16, 2022, that an independent committee is conducting an internal investigation concerning the AP-013 clinical trial and other trials. The FDA indicated that AP-013 data is insufficient to demonstrate efficacy for regulatory approval. Management reports no clinically meaningful effects in its COVID-19 trials. The committee is reviewing unauthorized use of the investigational drug, Ampion, and implemented safeguards. The company is exploring strategic alternatives, including capital raising and potential partnerships, but won't comment further during the investigation.